Clinical Trials Logo

Hematological Malignancies clinical trials

View clinical trials related to Hematological Malignancies.

Filter by:

NCT ID: NCT04959903 Recruiting - Clinical trials for Hematological Malignancies

Safety and Efficacy of SMART101 in Pediatric and Adult Patients With Hematological Malignancies After T Cell Depleted Allo-HSCT

Start date: March 31, 2022
Phase: Phase 1/Phase 2
Study type: Interventional

The purpose of this study is to evaluate the safety and the efficacy of SMART101 (Human T Lymphoid Progenitor (HTLP)) injection to accelerate immune reconstitution after T cell depleted allogeneic hematopoietic stem cell transplantation (HSCT) in adult and pediatric patients with hematological malignancies.

NCT ID: NCT04878822 Active, not recruiting - Covid-19 Clinical Trials

Immunogenicity of Covid-19 Vaccination for Patients With Hematological Malignancies

Start date: April 13, 2021
Phase:
Study type: Observational

Covid-19 is associated with a mortality rate of 33-37% in patients with hematological malignancies. At present, the anti-SARS-CoV-2 vaccination represents the most effective strategy for the prevention of Covid-19. Patients with malignancies were excluded from the trials leading to the approval of Comirnaty, Moderna, Vaxzevria and Janssen vaccines. The immunogenicity of these vaccines in immunocompromised patients or with hematological malignancies is an unmet clinical need. The aim of the study is to evaluate the efficacy of vaccination in adult patients with hematological malignancies, who received vaccination according to Italian rules and were in treatment at the Hematology Unit of Varese, Italy Efficacy will be evaluated in terms of serological response, cellular-mediated immune response and prevention of Covid-19. The duration of the study will be 24 months.

NCT ID: NCT04790747 Recruiting - Clinical trials for Hematological Malignancies

Sequential Radiotherapy With CAR-T Cells in the Treatment of Relapsed and Refractory Hematological Malignancies With Extramedullary Lesions

Start date: March 2021
Phase: Phase 1/Phase 2
Study type: Interventional

Clinical trial for the safety and efficacy of sequential radiotherapy with CAR-T cells in the treatment of relapsed and refractory hematological malignancies with extramedullary lesions

NCT ID: NCT04743388 Recruiting - COVID-19 Clinical Trials

Study of the Kinetics of Antibodies Against COVID-19 (SARS-CoV-2) and of Cellular Subpopulations of the Immune System

Start date: January 4, 2021
Phase:
Study type: Observational [Patient Registry]

Determination of both the degree and duration of the immunity provided after receiving the BNT162b2 vaccine against SARS-Cov-2.

NCT ID: NCT04662788 Not yet recruiting - Clinical trials for Hematological Malignancies

Clinical Study on the Safety and Effectiveness of NK Cells/Combined Monoclonal Antibodies in the Treatment of Hematological Malignancies

Start date: January 1, 2021
Phase: Early Phase 1
Study type: Interventional

Clinical study on the safety and effectiveness of NK cells/combined monoclonal antibodies in the treatment of hematological malignancies

NCT ID: NCT04657965 Not yet recruiting - Clinical trials for Hematological Malignancies

LMP1 CAR-T for Patients With LMP1 Positive Infectious Diseases and Hematological Malignancies

Start date: January 15, 2021
Phase: Early Phase 1
Study type: Interventional

A study of LMP1 CAR-T for patients with LMP1 positive infectious diseases and hematological malignancies

NCT ID: NCT04634552 Recruiting - Clinical trials for Hematological Malignancies

A Study of Talquetamab in Participants With Relapsed or Refractory Multiple Myeloma

MonumenTAL-1
Start date: February 1, 2021
Phase: Phase 2
Study type: Interventional

The purpose of this study is to evaluate the efficacy and safety of talquetamab in participants with relapsed or refractory multiple myeloma at the recommended Phase 2 dose(s) (RP2Ds) (Part 3).

NCT ID: NCT04557098 Active, not recruiting - Clinical trials for Hematological Malignancies

A Study of Teclistamab in Participants With Relapsed or Refractory Multiple Myeloma

MajesTEC-1
Start date: September 17, 2020
Phase: Phase 2
Study type: Interventional

The purpose of this study is to evaluate the efficacy of teclistamab at the recommended Phase 2 dose (RP2D).

NCT ID: NCT04352556 Recruiting - Clinical trials for SARS-CoV-2 Infection

COVID19-hematological Malignancies: the Italian Hematology Alliance

Start date: April 7, 2020
Phase:
Study type: Observational

This is a retrospective/prospective, cohort, non-interventional observational study. This means that all patients with documented COVID and HM diagnosed between February 2020 and study initiation will compose the retrospective part, while those diagnosed after study approval will enter prospective part. The total duration of the study will be 12 months. The study population will must be older than 18 years of age with HM and SARS-CoV-2 infection. All patients with documented SARS-CoV-2 infection (COVID) and history or active hematological malignancies, who refer to any Hematological Unit will be included.

NCT ID: NCT04283097 Recruiting - Clinical trials for Hematological Malignancies

Safety, Tolerability and Pharmacokinetics Study of KPG-818 in Hematological Malignancies Subjects

Start date: September 13, 2021
Phase: Phase 1
Study type: Interventional

This is a phase 1, multicenter, open-label, multiple-ascending dose study to evaluate the safety, pharmacokinetics and clinical activity of KPG-818 in subjects with hematological malignancies. Approximately 30 patients will be enrolled for dose escalation of 4 dose levels. Indication: Hematological malignancies (multiple myeloma [MM], mantle cell lymphoma [MCL], diffuse large B-cell lymphoma [DLBCL], adult T-cell leukemia-lymphoma [ATL], and indolent non Hodgkin lymphomas such as follicular lymphoma [FL] and chronic lymphocytic leukemia [CLL]/small lymphocytic lymphoma [SLL]).